March 2026 Research Update

This month added both real-world style clinical data and early-stage lab work that point in a similar direction: enzyme-based treatment can improve walking and some muscle measures, while researchers keep trying to make enzymes last longer in the body and cause fewer immune reactions. The clearest human signal came from a 52-week study of alglucosidase alfa showing better walking distance and several strength and quality-of-life measures, while breathing measures did not clearly improve. Alongside this, newer approaches aim to protect the enzyme (with miglustat) or change how it is delivered (with lipid nanoparticles), but those approaches range from review-level clinical evidence to mouse and cell experiments rather than new patient trial results this month. [1] [2] [3]

In 41 Chinese people with late-onset Pompe disease, 52 weeks of alglucosidase alfa was linked with a meaningful gain in walking distance on the 6-minute walk test, plus improvements in multiple muscle and motor measures and the physical part of a quality-of-life questionnaire. Breathing capacity (forced vital capacity) increased slightly but was not statistically significant in this single-arm study, which means the study did not show a clear breathing improvement over the year. Side effects were common but were mostly mild to moderate and were reported to resolve. [1]

A separate paper summarized clinical and preclinical evidence for pairing cipaglucosidase alfa (a newer enzyme replacement therapy) with miglustat (used here as an enzyme stabilizer, meaning it helps protect the enzyme in the bloodstream). The review described that miglustat increased exposure to cipaglucosidase alfa in adults and that the phase III PROPEL trial did not meet its main walking endpoint, while still reporting biomarker improvements and stabilization of breathing function, with generally tolerable side effects including gastrointestinal symptoms. Because this was a review, it pulled together earlier data rather than adding new trial results this month, but it clarifies what outcomes were mixed versus consistent in that program. [2]

Two early research studies focused on ways to potentially improve enzyme treatment in the future, but neither can yet tell patients what will happen in people. In mice, wrapping enzyme inside charge-driven lipid nanoparticles increased delivery to muscle cells, raised intracellular enzyme activity, and reduced anti-drug antibodies compared with free enzyme, including eliminating antibody-mediated infusion reactions in that model. In patient-derived cells, a newly designed multivalent pharmacological chaperone (a molecule meant to help the GAA enzyme fold or work better) increased GAA activity by about 1.2-fold at a very low dose, showing proof-of-concept in the lab. [3] [4]

For patients, this month strengthened the picture that enzyme replacement therapy can improve walking ability and some muscle-related outcomes over about 1 year, while breathing improvements may be harder to demonstrate in some studies. It also clarified that some next-generation strategies are trying to address practical problems with enzyme therapy, such as how long the enzyme stays active in the body and how the immune system responds, but the newest delivery and chaperone ideas are still at the mouse or cell stage. What remains uncertain is how well these experimental approaches will translate to long-term everyday function and breathing in diverse patient groups, because that requires larger and longer human studies. [1] [2] [3] [4]

This month brought multiple studies trying to measure late-onset Pompe disease changes more sensitively than traditional clinic tests, especially for walking patterns, strength, balance, and breathing. Across these studies, instrumented measurements (wearable gait features, dynamometer strength testing, and lung function imaging) detected differences between people with Pompe disease and controls and also picked up change over time. The shared message is that progression can be captured in more detailed ways than a single walking-distance score, which may matter for tracking the disease in research and potentially for monitoring in the future if validated. [5] [6] [7]

Wearable gait analysis was used to build a combined score called the Pompe-MDPI, which separated people with late-onset Pompe disease from matched controls with high accuracy and also changed over time in the Pompe group. The authors reported that this score outperformed the 6-minute walk distance for distinguishing Pompe from controls, and they also found gait patterns that suggested there may be subgroups within late-onset Pompe disease. In plain terms, this work suggests that how someone walks, measured in detail by sensors, might capture disease differences and progression even when standard tests are less clear. [5]

A separate 2-year follow-up study in adults reported measurable decline in specific leg muscle groups, walking speed, and balance-related measures when comparing changes over time in Pompe disease versus controls. Hip extensor and hip abductor strength, measured with more sensitive equipment, and walking speed were highlighted as particularly responsive to change, while manual muscle testing did not show significant change in the same period. This helps explain why some clinic measures can look stable even when more precise tools detect gradual weakening or balance changes. [6]

For breathing, a small pilot study tested a free-breathing lung MRI method (PREFUL MRI) and found lower average ventilation in adults with late-onset Pompe disease than in healthy volunteers, while lung perfusion looked similar between groups. Ventilation defect measures tended to relate to disease severity and to whether someone used noninvasive ventilation at night, and the scan was reported to be well tolerated with no adverse events. The practical meaning is that imaging might eventually provide a way to map where breathing is reduced across the lungs, not just a single number from a breathing test, but this approach still needs larger validation. [7]

For patients and caregivers, these studies mainly add understanding about how late-onset Pompe disease can be tracked and how subtle changes might be detected earlier. Right now, the findings are most relevant to research because the tools (wearable multi-feature scores, specialized strength equipment, and advanced lung MRI) are still being tested for reliability, practicality, and meaning across larger groups. What became clearer is that walking speed, certain hip and ankle strengths, and sensor-based gait features may capture progression over 2 years, and that lung ventilation changes may be visible on imaging even when lung structure looks normal. What remains uncertain is how these newer measurements compare head-to-head in routine care and how much a change in one of these scores translates to day-to-day abilities that matter most to patients. [5] [6] [7]

This month reinforced that the impact of Pompe disease goes well beyond muscle and breathing tests, affecting travel, finances, time demands on families, and the experience of getting a diagnosis. Across a cost-and-interview study in Thailand and a small survey of adults in the UK and USA, patients and caregivers described substantial ongoing burdens even when treatment is used. A separate case report also showed how standard genetic testing can miss certain Pompe-causing changes, which can contribute to delayed or uncertain diagnosis until more advanced testing is done. [8] [9] [10]

In Thailand, costs outside of enzyme replacement therapy were still sizeable and included medical costs, non-medical costs such as travel, and indirect costs such as lost productivity, alongside a reported need for informal caregiving in some families. Interviews described physical limitations as well as social, emotional, and financial strain, and travel to specialized centers could involve long distances and time. This provides concrete evidence that even when the main drug cost is excluded, managing Pompe disease can create a broad family burden that differs by healthcare setting and access. [8]

In a small online survey of adults living with late-onset Pompe disease in the UK and USA, many reported long delays between first symptoms and diagnosis and frequent misdiagnosis, alongside ongoing impacts on breathing, daily function, and pain. Most respondents reported using enzyme replacement therapy and many still described moderate to severe effects on everyday life and needs for information or psychosocial support. While this survey cannot represent everyone, it adds detail about the lived experience of navigating diagnosis and long-term symptoms in countries with established specialty care. [9]

A single case report highlighted one reason diagnosis can be difficult: some disease-causing genetic changes may sit deep within a gene and are not found by standard sequencing focused on typical regions. In a 5-year-old girl with Pompe disease, whole-gene sequencing plus RNA testing found a deep intronic GAA change that altered splicing, enabling a genetic diagnosis after earlier tests were negative. This illustrates that for a small subset of families, more specialized genetic and RNA testing can be needed to explain symptoms when initial testing is inconclusive. [10]

For patients and caregivers, these studies put numbers and narratives to burdens that families often already feel, including travel time, out-of-pocket costs, and the need for unpaid caregiving, and they show that these burdens can persist even when enzyme therapy is part of care. They also clarify that diagnostic delays can be long and that some genetic causes may be missed by first-line tests, which helps explain why the path to a clear diagnosis can be complicated for some people. What remains uncertain is how common deep intronic genetic changes are among undiagnosed or hard-to-diagnose patients, since the report was a single case. The main value this month is better documentation of the real-life and diagnostic challenges around Pompe disease, rather than new evidence about changing treatments. [8] [9] [10]